AKT1 and irritable bowel syndrome: These monoamines activate the extracellular signal-regulated kinase (ERK) pathway, which drives cellular stress responses, while inhibiting AKT (protein kinase B), a key regulator of insulin-stimulated glucose uptake, thereby resulting in insulin resistance in IBS and type 2 diabetes patients (23).